ASLAN PHARMACEUTICALS LIMITED

Insiders ASLAN Pharmaceuticals Limited

Equities

ASLN

US04522R2004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.4153 ^USD	-7.30%		-18.89%	-20.46%

Apr. 26	Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.5%	MT
Apr. 25	Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ASLAN Pharmaceuticals Limited Appoints Ramaswamy Krishnan and Reynold Panettieri as Scientific Advisors	Mar. 06	CI
ASLAN Pharmaceuticals Names Alex Kaoukhov as Chief Medical Officer	22-03-15	MT
ASLAN Pharmaceuticals Limited Appoints Dr. Alex Kaoukhov as Chief Medical Officer	22-03-15	CI
Kintara Therapeutics Names Robert E. Hoffman as CEO	21-11-09	MT
ASLAN Pharmaceuticals Appoints Melinda Jennifer Gooderham, Jacob Thyssen and Peter Foley as Members of Scientific Advisory Board	21-10-14	CI
ASLAN Pharmaceuticals Limited Announces Board Appointments	21-09-21	CI
ASLAN Pharmaceuticals Appoints Dr. Kathleen Metters as Independent Director	21-03-18	CI
ASLAN Pharmaceuticals Announces Executive Changes	21-02-18	CI
ASLAN Pharmaceuticals Appoints Kenneth Kobayashi, MD, as Chief Medical Officer	20-08-03	CI
ASLAN Pharmaceuticals Limited Announces Executive Changes	20-05-05	CI
ASLAN Pharmaceuticals Limited Names Andrew Howden as Non-Executive Chairman of the Board	19-07-26	CI
Aslan Pharmaceuticals Limited Announces the Change of Nomination Committee Members	19-07-26	CI
ASLAN Pharmaceuticals Limited Announces Executive Changes	19-01-29	CI
ASLAN Pharmaceuticals Limited Announces Remuneration and Audit Committee Changes	18-10-31	CI
ASLAN Pharmaceuticals Announces Board Changes	18-10-30	CI
ASLAN Pharmaceuticals Appoints Stephen Doyle as Head of China	18-01-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer